Ruanne Vanessa Barnabas, M.B.,Ch.B., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 110 | 2025 | 17530 | 5.910 |
Why?
|
Papillomavirus Vaccines | 16 | 2024 | 495 | 4.990 |
Why?
|
Papillomavirus Infections | 24 | 2024 | 1637 | 4.000 |
Why?
|
Uterine Cervical Neoplasms | 21 | 2024 | 2041 | 3.540 |
Why?
|
Anti-HIV Agents | 36 | 2025 | 4558 | 3.450 |
Why?
|
South Africa | 46 | 2025 | 1868 | 2.920 |
Why?
|
Viral Load | 29 | 2024 | 3385 | 2.180 |
Why?
|
Kenya | 30 | 2024 | 758 | 2.180 |
Why?
|
Sexual Partners | 12 | 2025 | 804 | 2.130 |
Why?
|
AIDS Serodiagnosis | 7 | 2018 | 220 | 1.510 |
Why?
|
Family Planning Services | 8 | 2023 | 277 | 1.480 |
Why?
|
Community Health Services | 5 | 2024 | 657 | 1.450 |
Why?
|
Immunization Schedule | 3 | 2024 | 229 | 1.450 |
Why?
|
Post-Exposure Prophylaxis | 4 | 2022 | 113 | 1.390 |
Why?
|
Counseling | 14 | 2025 | 1551 | 1.340 |
Why?
|
Cost-Benefit Analysis | 26 | 2022 | 5529 | 1.330 |
Why?
|
Hydroxychloroquine | 5 | 2023 | 427 | 1.280 |
Why?
|
Antiviral Agents | 5 | 2020 | 3051 | 1.190 |
Why?
|
Tuberculosis | 5 | 2024 | 2013 | 1.070 |
Why?
|
HIV-1 | 21 | 2024 | 6943 | 1.050 |
Why?
|
Models, Theoretical | 13 | 2021 | 3563 | 1.050 |
Why?
|
Models, Economic | 4 | 2022 | 716 | 1.020 |
Why?
|
Anti-Retroviral Agents | 12 | 2023 | 1786 | 0.950 |
Why?
|
Rural Population | 11 | 2024 | 2317 | 0.900 |
Why?
|
Heterosexuality | 6 | 2020 | 308 | 0.890 |
Why?
|
Mass Screening | 18 | 2023 | 5445 | 0.890 |
Why?
|
CD4 Lymphocyte Count | 12 | 2022 | 2586 | 0.860 |
Why?
|
Alphapapillomavirus | 3 | 2022 | 219 | 0.830 |
Why?
|
Acyclovir | 2 | 2015 | 266 | 0.830 |
Why?
|
Isoniazid | 3 | 2021 | 279 | 0.810 |
Why?
|
Herpesvirus 2, Human | 3 | 2015 | 191 | 0.800 |
Why?
|
Home Care Services | 7 | 2018 | 660 | 0.790 |
Why?
|
Africa South of the Sahara | 11 | 2020 | 751 | 0.770 |
Why?
|
Continuity of Patient Care | 3 | 2020 | 1076 | 0.740 |
Why?
|
Contact Tracing | 3 | 2020 | 274 | 0.740 |
Why?
|
Herpes Genitalis | 3 | 2014 | 148 | 0.730 |
Why?
|
Pharmacies | 2 | 2024 | 171 | 0.710 |
Why?
|
Schistosomiasis haematobia | 1 | 2020 | 16 | 0.700 |
Why?
|
Uganda | 9 | 2021 | 1353 | 0.690 |
Why?
|
Circumcision, Male | 6 | 2019 | 148 | 0.690 |
Why?
|
Young Adult | 42 | 2024 | 59849 | 0.680 |
Why?
|
Human papillomavirus 16 | 5 | 2024 | 268 | 0.680 |
Why?
|
Delivery of Health Care | 10 | 2023 | 5368 | 0.660 |
Why?
|
Schistosomiasis mansoni | 1 | 2020 | 94 | 0.660 |
Why?
|
Female | 108 | 2025 | 396050 | 0.650 |
Why?
|
Schistosomiasis | 1 | 2019 | 65 | 0.650 |
Why?
|
Diagnostic Tests, Routine | 4 | 2019 | 788 | 0.630 |
Why?
|
Vaccination | 11 | 2024 | 3425 | 0.630 |
Why?
|
Case Management | 1 | 2020 | 277 | 0.610 |
Why?
|
Humans | 150 | 2025 | 765823 | 0.600 |
Why?
|
Adolescent | 46 | 2024 | 88794 | 0.590 |
Why?
|
Antiretroviral Therapy, Highly Active | 6 | 2018 | 1899 | 0.590 |
Why?
|
Medication Adherence | 4 | 2025 | 2190 | 0.590 |
Why?
|
Health Services Needs and Demand | 3 | 2019 | 1405 | 0.590 |
Why?
|
Adult | 73 | 2025 | 223055 | 0.570 |
Why?
|
Vaginosis, Bacterial | 1 | 2019 | 154 | 0.560 |
Why?
|
Infectious Disease Transmission, Vertical | 5 | 2021 | 1353 | 0.560 |
Why?
|
Chemoprevention | 2 | 2018 | 327 | 0.540 |
Why?
|
Self Report | 3 | 2024 | 3768 | 0.520 |
Why?
|
Pregnancy Complications, Infectious | 6 | 2021 | 2184 | 0.510 |
Why?
|
Disease Transmission, Infectious | 2 | 2018 | 560 | 0.500 |
Why?
|
Precancerous Conditions | 2 | 2023 | 975 | 0.500 |
Why?
|
Antibiotic Prophylaxis | 1 | 2021 | 642 | 0.500 |
Why?
|
Human papillomavirus 18 | 4 | 2024 | 125 | 0.490 |
Why?
|
Health Care Costs | 6 | 2024 | 3240 | 0.490 |
Why?
|
Systems Analysis | 5 | 2023 | 168 | 0.490 |
Why?
|
Male | 76 | 2025 | 363740 | 0.470 |
Why?
|
Prevalence | 17 | 2024 | 15832 | 0.460 |
Why?
|
Program Evaluation | 4 | 2021 | 2501 | 0.460 |
Why?
|
AIDS Vaccines | 3 | 2021 | 898 | 0.460 |
Why?
|
Motivation | 3 | 2021 | 2018 | 0.450 |
Why?
|
Virus Shedding | 3 | 2022 | 111 | 0.440 |
Why?
|
Incidence | 18 | 2024 | 21501 | 0.440 |
Why?
|
Randomized Controlled Trials as Topic | 10 | 2023 | 10383 | 0.440 |
Why?
|
Sexually Transmitted Diseases | 4 | 2022 | 667 | 0.430 |
Why?
|
AIDS-Related Opportunistic Infections | 2 | 2021 | 663 | 0.430 |
Why?
|
Antitubercular Agents | 2 | 2021 | 1382 | 0.420 |
Why?
|
Papillomaviridae | 4 | 2023 | 1137 | 0.410 |
Why?
|
Patient Acceptance of Health Care | 3 | 2024 | 3229 | 0.410 |
Why?
|
Costs and Cost Analysis | 1 | 2018 | 1667 | 0.410 |
Why?
|
Herpes Zoster | 1 | 2015 | 252 | 0.410 |
Why?
|
Ambulatory Care Facilities | 5 | 2023 | 937 | 0.390 |
Why?
|
Resource Allocation | 1 | 2014 | 354 | 0.380 |
Why?
|
National Health Programs | 1 | 2015 | 443 | 0.380 |
Why?
|
Epidemiologic Studies | 1 | 2014 | 677 | 0.360 |
Why?
|
Health Personnel | 1 | 2024 | 3386 | 0.360 |
Why?
|
Epidemics | 1 | 2016 | 513 | 0.350 |
Why?
|
Occupational Exposure | 1 | 2020 | 1805 | 0.330 |
Why?
|
Patient Selection | 1 | 2022 | 4257 | 0.330 |
Why?
|
Early Detection of Cancer | 9 | 2024 | 3237 | 0.330 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 2022 | 2204 | 0.320 |
Why?
|
Middle Aged | 37 | 2025 | 223016 | 0.310 |
Why?
|
Prenatal Care | 4 | 2022 | 1157 | 0.300 |
Why?
|
HIV Seropositivity | 3 | 2023 | 961 | 0.300 |
Why?
|
Herpes Simplex | 1 | 2011 | 470 | 0.290 |
Why?
|
Sexual Behavior | 7 | 2024 | 2192 | 0.290 |
Why?
|
Africa, Southern | 2 | 2024 | 60 | 0.280 |
Why?
|
Heterocyclic Compounds, 3-Ring | 2 | 2020 | 295 | 0.270 |
Why?
|
HIV | 5 | 2024 | 1585 | 0.260 |
Why?
|
Double-Blind Method | 6 | 2023 | 12421 | 0.250 |
Why?
|
Pregnancy | 19 | 2024 | 30215 | 0.230 |
Why?
|
Tanzania | 4 | 2024 | 1407 | 0.230 |
Why?
|
Pandemics | 7 | 2024 | 8698 | 0.230 |
Why?
|
Pilot Projects | 4 | 2025 | 8725 | 0.220 |
Why?
|
Contraceptive Devices, Female | 1 | 2023 | 39 | 0.210 |
Why?
|
Coitus | 1 | 2023 | 133 | 0.200 |
Why?
|
Men's Health | 2 | 2020 | 75 | 0.200 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2018 | 4046 | 0.200 |
Why?
|
Treatment Outcome | 11 | 2021 | 65223 | 0.200 |
Why?
|
Africa | 2 | 2022 | 725 | 0.190 |
Why?
|
Homosexuality, Male | 7 | 2023 | 1342 | 0.190 |
Why?
|
Malaria | 1 | 2011 | 1246 | 0.190 |
Why?
|
Immunization Programs | 1 | 2024 | 267 | 0.190 |
Why?
|
Serologic Tests | 2 | 2022 | 382 | 0.180 |
Why?
|
Patient Compliance | 2 | 2023 | 2693 | 0.180 |
Why?
|
Schistosoma haematobium | 1 | 2020 | 14 | 0.180 |
Why?
|
Anus Neoplasms | 1 | 2024 | 336 | 0.170 |
Why?
|
Risk Factors | 15 | 2022 | 74853 | 0.170 |
Why?
|
Marriage | 1 | 2021 | 351 | 0.170 |
Why?
|
Prospective Studies | 10 | 2023 | 54798 | 0.160 |
Why?
|
Unsafe Sex | 1 | 2021 | 239 | 0.160 |
Why?
|
Schistosoma mansoni | 1 | 2020 | 154 | 0.160 |
Why?
|
Genitalia | 1 | 2019 | 114 | 0.160 |
Why?
|
Multicenter Studies as Topic | 2 | 2022 | 1731 | 0.150 |
Why?
|
Preventive Medicine | 1 | 2020 | 246 | 0.150 |
Why?
|
Maternal Welfare | 1 | 2019 | 113 | 0.150 |
Why?
|
HIV Seroprevalence | 1 | 2018 | 89 | 0.150 |
Why?
|
Models, Organizational | 2 | 2019 | 548 | 0.150 |
Why?
|
RNA, Viral | 3 | 2022 | 2863 | 0.150 |
Why?
|
Benzoxazines | 1 | 2020 | 320 | 0.150 |
Why?
|
Zambia | 1 | 2018 | 273 | 0.150 |
Why?
|
Syphilis | 1 | 2020 | 243 | 0.150 |
Why?
|
Markov Chains | 2 | 2020 | 971 | 0.150 |
Why?
|
Trichomonas Vaginitis | 1 | 2017 | 33 | 0.140 |
Why?
|
Endemic Diseases | 2 | 2021 | 189 | 0.140 |
Why?
|
Ascorbic Acid | 1 | 2020 | 657 | 0.140 |
Why?
|
Pregnant Women | 1 | 2021 | 575 | 0.140 |
Why?
|
House Calls | 1 | 2019 | 171 | 0.140 |
Why?
|
Mass Vaccination | 1 | 2018 | 111 | 0.140 |
Why?
|
Trichomonas vaginalis | 1 | 2017 | 70 | 0.130 |
Why?
|
HIV Integrase Inhibitors | 1 | 2018 | 164 | 0.130 |
Why?
|
Patient Preference | 1 | 2024 | 947 | 0.130 |
Why?
|
Poverty | 2 | 2019 | 2714 | 0.130 |
Why?
|
Plasma | 1 | 2019 | 579 | 0.130 |
Why?
|
Postnatal Care | 1 | 2018 | 274 | 0.130 |
Why?
|
HIV Seronegativity | 1 | 2017 | 209 | 0.130 |
Why?
|
Cross-Sectional Studies | 7 | 2024 | 26276 | 0.130 |
Why?
|
Primary Prevention | 2 | 2013 | 1187 | 0.120 |
Why?
|
World Health Organization | 2 | 2021 | 1326 | 0.120 |
Why?
|
Community Networks | 1 | 2017 | 202 | 0.120 |
Why?
|
Cohort Studies | 5 | 2022 | 41643 | 0.120 |
Why?
|
Models, Statistical | 3 | 2018 | 5089 | 0.120 |
Why?
|
Risk Assessment | 7 | 2021 | 24278 | 0.120 |
Why?
|
Telemedicine | 3 | 2022 | 3106 | 0.120 |
Why?
|
Saliva | 1 | 2019 | 851 | 0.120 |
Why?
|
Primary Health Care | 2 | 2021 | 4735 | 0.110 |
Why?
|
Case-Control Studies | 3 | 2022 | 22227 | 0.110 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2021 | 837 | 0.110 |
Why?
|
Self Care | 1 | 2019 | 800 | 0.110 |
Why?
|
Referral and Consultation | 3 | 2018 | 3614 | 0.110 |
Why?
|
Family Characteristics | 2 | 2016 | 1001 | 0.110 |
Why?
|
Directive Counseling | 1 | 2015 | 171 | 0.110 |
Why?
|
Occupational Health | 1 | 2020 | 812 | 0.110 |
Why?
|
Prenatal Diagnosis | 1 | 2020 | 1270 | 0.110 |
Why?
|
Critical Pathways | 1 | 2017 | 475 | 0.110 |
Why?
|
Quality-Adjusted Life Years | 2 | 2019 | 1740 | 0.110 |
Why?
|
Aged, 80 and over | 5 | 2022 | 59506 | 0.110 |
Why?
|
Reward | 1 | 2020 | 980 | 0.110 |
Why?
|
Administration, Oral | 1 | 2021 | 4018 | 0.100 |
Why?
|
Point-of-Care Systems | 3 | 2017 | 1216 | 0.100 |
Why?
|
Infection Control | 1 | 2020 | 982 | 0.100 |
Why?
|
Attitude of Health Personnel | 2 | 2024 | 3925 | 0.100 |
Why?
|
Research | 1 | 2021 | 1974 | 0.100 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3099 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3222 | 0.100 |
Why?
|
HIV Antibodies | 1 | 2019 | 1337 | 0.100 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4849 | 0.100 |
Why?
|
Child | 9 | 2024 | 80509 | 0.100 |
Why?
|
Health Plan Implementation | 1 | 2014 | 338 | 0.090 |
Why?
|
Developing Countries | 2 | 2021 | 2913 | 0.090 |
Why?
|
Eligibility Determination | 1 | 2015 | 422 | 0.090 |
Why?
|
Health Resources | 1 | 2017 | 949 | 0.090 |
Why?
|
Data Collection | 1 | 2020 | 3317 | 0.090 |
Why?
|
Gender Identity | 1 | 2017 | 766 | 0.090 |
Why?
|
Social Perception | 1 | 2015 | 435 | 0.090 |
Why?
|
Placebos | 1 | 2015 | 1659 | 0.090 |
Why?
|
Sex Distribution | 1 | 2015 | 2268 | 0.090 |
Why?
|
Perception | 1 | 2017 | 1204 | 0.090 |
Why?
|
Aged | 11 | 2024 | 171178 | 0.090 |
Why?
|
Time Factors | 3 | 2020 | 40109 | 0.090 |
Why?
|
Injections, Subcutaneous | 2 | 2022 | 682 | 0.080 |
Why?
|
Cost of Illness | 1 | 2019 | 1949 | 0.080 |
Why?
|
DNA Methylation | 1 | 2024 | 4424 | 0.080 |
Why?
|
Seroepidemiologic Studies | 2 | 2014 | 404 | 0.080 |
Why?
|
Income | 1 | 2017 | 1873 | 0.080 |
Why?
|
Health Status | 1 | 2021 | 4084 | 0.080 |
Why?
|
Focus Groups | 3 | 2024 | 1459 | 0.080 |
Why?
|
Patient Participation | 1 | 2017 | 1448 | 0.070 |
Why?
|
Age Factors | 3 | 2020 | 18380 | 0.070 |
Why?
|
Specimen Handling | 2 | 2024 | 703 | 0.070 |
Why?
|
Chronic Disease | 2 | 2021 | 9355 | 0.070 |
Why?
|
Oxazines | 2 | 2020 | 358 | 0.070 |
Why?
|
Patient Education as Topic | 1 | 2016 | 2331 | 0.060 |
Why?
|
Health Services Accessibility | 3 | 2019 | 5508 | 0.060 |
Why?
|
Qualitative Research | 3 | 2024 | 3135 | 0.060 |
Why?
|
Drug Combinations | 2 | 2022 | 2074 | 0.060 |
Why?
|
Survival Analysis | 1 | 2018 | 10087 | 0.060 |
Why?
|
Australia | 1 | 2008 | 1259 | 0.060 |
Why?
|
Drug Resistance, Viral | 2 | 2021 | 866 | 0.060 |
Why?
|
Finland | 1 | 2006 | 608 | 0.060 |
Why?
|
Vulnerable Populations | 2 | 2020 | 718 | 0.060 |
Why?
|
Disease Progression | 2 | 2022 | 13613 | 0.060 |
Why?
|
Virus Replication | 1 | 2012 | 2446 | 0.060 |
Why?
|
United States | 3 | 2020 | 72896 | 0.060 |
Why?
|
Pyridones | 2 | 2020 | 816 | 0.060 |
Why?
|
Quality Improvement | 1 | 2019 | 3845 | 0.050 |
Why?
|
Severity of Illness Index | 1 | 2022 | 15881 | 0.050 |
Why?
|
Acetic Acid | 1 | 2023 | 58 | 0.050 |
Why?
|
Paired Box Transcription Factors | 1 | 2024 | 204 | 0.050 |
Why?
|
Licensure | 1 | 2024 | 128 | 0.050 |
Why?
|
Georgia | 1 | 2023 | 186 | 0.050 |
Why?
|
Entrepreneurship | 1 | 2022 | 23 | 0.050 |
Why?
|
Lesotho | 1 | 2022 | 77 | 0.050 |
Why?
|
History, 20th Century | 2 | 2020 | 2761 | 0.050 |
Why?
|
Contraception Behavior | 1 | 2024 | 185 | 0.050 |
Why?
|
Postpartum Period | 2 | 2021 | 1196 | 0.050 |
Why?
|
Factor Analysis, Statistical | 1 | 2024 | 999 | 0.050 |
Why?
|
Condoms | 1 | 2023 | 336 | 0.050 |
Why?
|
Depression | 1 | 2021 | 8224 | 0.050 |
Why?
|
Asymptomatic Infections | 1 | 2022 | 136 | 0.050 |
Why?
|
Antibodies, Viral | 2 | 2024 | 3210 | 0.050 |
Why?
|
Viral Vaccines | 1 | 2006 | 597 | 0.040 |
Why?
|
Chlamydia trachomatis | 1 | 2022 | 240 | 0.040 |
Why?
|
Zimbabwe | 1 | 2020 | 135 | 0.040 |
Why?
|
Ukraine | 1 | 2020 | 151 | 0.040 |
Why?
|
Doxycycline | 1 | 2022 | 348 | 0.040 |
Why?
|
Longitudinal Studies | 3 | 2022 | 14745 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2012 | 10723 | 0.040 |
Why?
|
Colombia | 1 | 2020 | 288 | 0.040 |
Why?
|
Depressive Disorder, Major | 1 | 2017 | 4805 | 0.040 |
Why?
|
Public Sector | 1 | 2021 | 264 | 0.040 |
Why?
|
Mozambique | 1 | 2019 | 55 | 0.040 |
Why?
|
Peru | 1 | 2022 | 887 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2017 | 39226 | 0.040 |
Why?
|
Alkynes | 1 | 2020 | 326 | 0.040 |
Why?
|
Bisexuality | 1 | 2021 | 295 | 0.040 |
Why?
|
Piperazines | 2 | 2020 | 2546 | 0.040 |
Why?
|
Cyclopropanes | 1 | 2020 | 437 | 0.040 |
Why?
|
Netherlands | 1 | 2023 | 2277 | 0.040 |
Why?
|
Asymptomatic Diseases | 1 | 2021 | 584 | 0.040 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2024 | 1137 | 0.040 |
Why?
|
Canada | 1 | 2023 | 2119 | 0.040 |
Why?
|
Clinical Trials as Topic | 2 | 2024 | 8039 | 0.040 |
Why?
|
Washington | 1 | 2018 | 314 | 0.040 |
Why?
|
DNA, Viral | 1 | 2024 | 2199 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2024 | 14644 | 0.030 |
Why?
|
Forecasting | 1 | 2006 | 2938 | 0.030 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2022 | 614 | 0.030 |
Why?
|
Risk-Taking | 2 | 2013 | 1021 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2023 | 856 | 0.030 |
Why?
|
Public Health | 2 | 2021 | 2678 | 0.030 |
Why?
|
DNA, Protozoan | 1 | 2017 | 226 | 0.030 |
Why?
|
Antibody Formation | 1 | 2021 | 1391 | 0.030 |
Why?
|
Predictive Value of Tests | 2 | 2024 | 15398 | 0.030 |
Why?
|
Population Surveillance | 1 | 2006 | 2595 | 0.030 |
Why?
|
Research Design | 2 | 2024 | 6207 | 0.030 |
Why?
|
Hemorrhagic Fever, Ebola | 1 | 2020 | 424 | 0.030 |
Why?
|
Models, Biological | 1 | 2011 | 9441 | 0.030 |
Why?
|
Retrospective Studies | 1 | 2024 | 81505 | 0.030 |
Why?
|
Drug Resistance | 1 | 2021 | 1590 | 0.030 |
Why?
|
Organizational Innovation | 1 | 2018 | 540 | 0.030 |
Why?
|
Efficiency | 1 | 2018 | 479 | 0.030 |
Why?
|
Kinetics | 1 | 2022 | 6272 | 0.030 |
Why?
|
Domestic Violence | 1 | 2016 | 180 | 0.030 |
Why?
|
Workflow | 1 | 2019 | 857 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2022 | 1084 | 0.030 |
Why?
|
History, 21st Century | 1 | 2020 | 1573 | 0.030 |
Why?
|
Drug Monitoring | 1 | 2020 | 960 | 0.030 |
Why?
|
Americas | 1 | 2013 | 109 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2018 | 1187 | 0.030 |
Why?
|
Europe | 1 | 2020 | 3427 | 0.030 |
Why?
|
Program Development | 1 | 2019 | 1296 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2022 | 6061 | 0.020 |
Why?
|
Schools | 1 | 2021 | 1495 | 0.020 |
Why?
|
Health Services Research | 1 | 2019 | 1811 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2019 | 2424 | 0.020 |
Why?
|
Neoplasms | 1 | 2019 | 22349 | 0.020 |
Why?
|
Chlamydia Infections | 1 | 2014 | 364 | 0.020 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2014 | 391 | 0.020 |
Why?
|
Developmental Disabilities | 1 | 2018 | 1519 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2015 | 1438 | 0.020 |
Why?
|
ROC Curve | 1 | 2017 | 3617 | 0.020 |
Why?
|
Hyperglycemia | 1 | 2017 | 1390 | 0.020 |
Why?
|
Mortality | 1 | 2020 | 2910 | 0.020 |
Why?
|
Social Stigma | 1 | 2015 | 787 | 0.020 |
Why?
|
Animals | 1 | 2020 | 168730 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2013 | 4056 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2015 | 2741 | 0.020 |
Why?
|
Communication | 1 | 2021 | 3906 | 0.020 |
Why?
|
Ambulatory Care | 1 | 2018 | 2776 | 0.020 |
Why?
|
Mental Health | 1 | 2021 | 3271 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2024 | 20131 | 0.020 |
Why?
|
Pregnancy Complications | 1 | 2020 | 2970 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2017 | 12056 | 0.010 |
Why?
|
Blood Glucose | 1 | 2017 | 6422 | 0.010 |
Why?
|
Logistic Models | 1 | 2017 | 13266 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7416 | 0.010 |
Why?
|
Infant | 1 | 2021 | 36375 | 0.010 |
Why?
|
Computer Simulation | 1 | 2011 | 6252 | 0.010 |
Why?
|
Hypertension | 1 | 2017 | 8625 | 0.010 |
Why?
|
Child, Preschool | 1 | 2020 | 42478 | 0.010 |
Why?
|
Obesity | 1 | 2017 | 13078 | 0.010 |
Why?
|